Where guidance meets the local antibiogram: a three-year, single-center laboratory-based study of ertapenem-only nonsusceptibility, cefotaxime–ceftazidime discordance, and urinary susceptibility in Enterobacterales
Year: 2026
Type: article
Abstract: Background Local antibiograms are essential for monitoring resistance and adapting treatment guidance to available antibiotics in resource-constrained settings. We examined resistance trends, discordant β-lactam susceptibility, and urinary susceptibility profiles in Enterobacterales to identify stewardship priorities. Methods This three-year, single-center, laboratory-based retrospective cross-sectional study included Enterobacterales from reporting years 2023–2025. We retained the first isolate per patient, species, and year. Resistance definitions incorporated the imipenem exception for Morganella , Proteus , and Providencia . Ertapenem-only nonsusceptibility required ertapenem nonsusceptibility and susceptibility to both meropenem and imipenem. Annual trends were assessed using the Cochran–Armitage test. Results Of 2,190 Enterobacterales isolates, 1,638 from 1,320 patients were retained. The proportion of isolates with carbapenem resistance declined from 8.4% in 2023 to 2.7% in 2025, and carbapenem nonsusceptibility from 12.6% to 5.4% (both p < 0.001). Cefotaxime resistance remained between 27.7% and 30.3% ( p = 0.483). Selectively missing ertapenem results in 2023–2024 restricted ertapenem-specific interpretation to 2025. In 2025, nine of 34 carbapenem-nonsusceptible isolates (26.5%) exhibited ertapenem-only nonsusceptibility. Among 252 cefotaxime-resistant urinary isolates without carbapenem nonsusceptibility, susceptibility was 29.8% to trimethoprim/sulfamethoxazole, 6.7% to ciprofloxacin, and 4.5% to levofloxacin. Nitrofurantoin susceptibility was 96.2% in Escherichia coli and 37.1% in Klebsiella pneumoniae . Among 463 cefotaxime-resistant isolates, 134 (28.9%) remained susceptible to ceftazidime; this proportion increased from 23.3% to 37.3% ( p = 0.006). Urinary carbapenem nonsusceptibility ranged from 3.7% in outpatients to 12.7% in inpatients. Conclusion Local antibiograms can guide the application of treatment guidance and prioritize genotyping and clinical studies of retained antibiotic activity. These laboratory findings do not establish resistance mechanisms, infection incidence, or treatment efficacy.
Source: Frontiers in Public Health
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: Enterobacterales, carbapenem resistance, cefotaxime resistance, urinary tract infection, antimicrobial resistance trends, antimicrobial stewardship, trimethoprim-sulfamethoxazole, nitrofurantoin, Escherichia coli, Klebsiella pneumoniae, Morganella, Proteus, Providencia, resource-limited settings
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236255350
